EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity-Reference-Cited by-同舟云学术

EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity

Published:2015-03-18 Issue:5 Volume:6 Page:491-495
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Campbell John E.¹,Kuntz Kevin W.¹,Knutson Sarah K.¹,Warholic Natalie M.¹,Keilhack Heike¹,Wigle Tim J.¹,Raimondi Alejandra¹,Klaus Christine R.¹,Rioux Nathalie¹,Yokoi Akira²,Kawano Satoshi²,Minoshima Yukinori²,Choi Hyeong-Wook³,Porter Scott Margaret¹,Waters Nigel J.¹,Smith Jesse J.¹,Chesworth Richard¹,Moyer Mikel P.¹,Copeland Robert A.¹

Affiliation:

1. Epizyme, Inc., 400 Technology Square, Fourth Floor, Cambridge, Massachusetts 02139, United States

2. Eisai Co., Ltd., Tokodai 5-1-3, Tsukuba, Ibarakai 300-2635, Japan

3. Eisai, Inc., 4 Corporate Drive, Andover, Massachusetts 01810, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5b00037

Reference16 articles.

1. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein